Home › Companies › Spyre Therapeutics, Inc. › 2025-2026
Compiled from SEC Form N-PX filings and Spyre Therapeutics, Inc.’s Form 8-K, filed 2026-05-29 (Item 5.07 on EDGAR). Page generated 04 October 2026.
Proxy season: 2024-2025 2025-2026
Explore Spyre Therapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are Spyre Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-05-29 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Mark McKenna | 65,608,709 | -- | -- | 1,329,489 | 1,500,346 | Majority: yes |
| Elect Director: Cameron Turtle, D. Phil. | 66,176,245 | -- | -- | 761,953 | 1,500,346 | Majority: yes |
| Elect Director: Laurie Stelzer | 56,954,664 | -- | -- | 9,983,534 | 1,500,346 | Majority: yes |
| Proposal 2: The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers. | 62,075,459 | 4,760,373 | 102,366 | -- | 1,500,346 | Majority: yes |
| Proposal 3: The Company's stockholders ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026. | 68,430,566 | 670 | 7,308 | -- | 0 | Majority: yes |
| Proposal 4: The Company's stockholders approved the Company's AR ESPP. | 66,885,864 | 45,542 | 6,792 | -- | 1,500,346 | Majority: yes |
Source: Spyre Therapeutics, Inc., Form 8-K, filed with the SEC on 2026-05-29 — read the filing on EDGAR.
Each item below shows how the 220 asset managers that disclosed a Spyre Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Spyre Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 8 wordings of this item as funds reported it.
93% Majority: yes · of votes cast
Spyre Therapeutics, Inc.’s own tally for this item (“Proposal 2: The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers.”): 62,075,459 for, 4,760,373 against, per its Form 8-K filed 2026-05-29 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 78,839,858 outstanding shares: 79% for, 6% against (85% of the company cast a for/against vote).
The 219 asset managers below cast 90% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 20,591,177 | 0 | 0 | 0 | For |
| Capital Group | 0 | 4,825,386 | 0 | 0 | Against |
| RTW INVESTMENTS, LP | 4,191,364 | 0 | 0 | 0 | For |
| Vanguard | 4,145,029 | 2,682 | 0 | 0 | For |
| Fairmount Funds Management LLC | 4,018,101 | 0 | 0 | 0 | For |
| Venrock Adviser, LLC | 3,685,448 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,962,670 | 0 | 0 | 0 | For |
| BlackRock | 2,675,936 | 7,794 | 0 | 0 | For |
| PERCEPTIVE ADVISORS LLC | 2,587,491 | 0 | 0 | 0 | For |
| Commodore Capital LP | 1,806,463 | 0 | 0 | 0 | For |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 1,666,378 | 0 | 0 | 0 | For |
| State Street | 1,653,554 | 10,432 | 0 | 0 | For |
| RA CAPITAL MANAGEMENT, L.P. | 1,621,620 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,593,687 | 0 | 0 | 0 | For |
| Polar Capital Holdings Plc | 1,499,662 | 0 | 0 | 0 | For |
| Remedium Capital Partners, LLC | 1,456,231 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 1,124,426 | 0 | 0 | Against |
| Wellington | 1,070,333 | 0 | 0 | 0 | For |
| BRAIDWELL LP | 932,823 | 0 | 0 | 0 | For |
| FRANKLIN ADVISERS INC | 879,501 | 0 | 0 | 0 | For |
| Siren, L.L.C. | 818,598 | 0 | 0 | 0 | For |
| Victory Capital | 688,340 | 0 | 0 | 0 | For |
| Caligan Partners LP | 662,832 | 0 | 0 | 0 | For |
| Affinity Asset Advisors, LLC | 591,286 | 0 | 0 | 0 | For |
| JPMorgan | 524,511 | 0 | 0 | 0 | For |
Showing the 25 largest of 219 asset managers. See all 219 in the interactive database.
Combines 7 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Spyre Therapeutics, Inc.’s own tally for this item (“Elect Director: Cameron Turtle, D. Phil.”): 66,176,245 for, 761,953 withheld, per its Form 8-K filed 2026-05-29 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 78,839,858 outstanding shares: 84% for, 1.0% withheld (85% of the company cast a for/withheld vote).
The 67 asset managers below cast 100% of the shares they voted on this item FOR (24,544,893 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 9,366,962 | 0 | 0 | 0 | For |
| Vanguard | 3,604,700 | 0 | 1 | 0 | For |
| Capital Group | 2,412,693 | 0 | 0 | 0 | For |
| BlackRock | 2,015,808 | 0 | 0 | 0 | For |
| Remedium Capital Partners, LLC | 1,456,231 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,262,166 | 0 | 0 | 0 | For |
| State Street | 658,596 | 0 | 0 | 0 | For |
| Charles Schwab | 561,767 | 0 | 0 | 0 | For |
| JPMorgan | 524,155 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 414,759 | 0 | 0 | 0 | For |
| Victory Capital | 326,801 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 323,584 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 65,274 | 0 | 252,945 | 0 | Abstain |
| First Trust | 178,135 | 0 | 0 | 0 | For |
| Hartford | 168,893 | 0 | 0 | 0 | For |
| Principal | 4,299 | 0 | 155,168 | 0 | Abstain |
| Equitable | 157,755 | 0 | 0 | 0 | For |
| TIAA | 144,924 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 82,062 | 0 | 0 | 0 | For |
| Brighthouse | 77,601 | 0 | 3,558 | 0 | For |
| Northwestern Mutual | 74,126 | 0 | 0 | 0 | For |
| Jackson National | 67,170 | 0 | 0 | 0 | For |
| John Hancock | 60,959 | 0 | 0 | 0 | For |
| Lincoln Financial | 52,674 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 49,311 | 0 | 0 | 0 | For |
Showing the 25 largest of 67 asset managers. See all 67 in the interactive database.
Combines 7 wordings of this item as funds reported it.
85% Majority: yes · of votes cast
Spyre Therapeutics, Inc.’s own tally for this item (“Elect Director: Laurie Stelzer”): 56,954,664 for, 9,983,534 withheld, per its Form 8-K filed 2026-05-29 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 78,839,858 outstanding shares: 72% for, 13% withheld (85% of the company cast a for/withheld vote).
The 67 asset managers below cast 100% of the shares they voted on this item FOR (22,279,236 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 9,366,962 | 0 | 0 | 0 | For |
| Vanguard | 3,602,011 | 0 | 2,689 | 0 | For |
| Capital Group | 2,412,693 | 0 | 0 | 0 | For |
| BlackRock | 2,015,808 | 0 | 0 | 0 | For |
| Remedium Capital Partners, LLC | 1,456,231 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,262,166 | 0 | 0 | 0 | For |
| State Street | 1,384 | 0 | 657,212 | 0 | Abstain |
| Charles Schwab | 561,767 | 0 | 0 | 0 | For |
| JPMorgan | 524,155 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 0 | 0 | 414,759 | 0 | Abstain |
| Victory Capital | 0 | 0 | 326,801 | 0 | Abstain |
| FRANKLIN STRATEGIC SERIES | 323,584 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 0 | 0 | 318,219 | 0 | Abstain |
| First Trust | 0 | 0 | 178,135 | 0 | Abstain |
| Hartford | 168,893 | 0 | 0 | 0 | For |
| Principal | 0 | 0 | 159,467 | 0 | Abstain |
| Equitable | 112,825 | 0 | 44,930 | 0 | For |
| TIAA | 144,924 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 0 | 0 | 82,062 | 0 | Abstain |
| Brighthouse | 53,625 | 0 | 27,534 | 0 | For |
| Northwestern Mutual | 74,126 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 67,170 | 0 | Abstain |
| John Hancock | 42,692 | 0 | 18,267 | 0 | For |
| Lincoln Financial | 7,274 | 0 | 45,400 | 0 | Abstain |
| Columbia Threadneedle | 0 | 0 | 49,311 | 0 | Abstain |
Showing the 25 largest of 67 asset managers. See all 67 in the interactive database.
Combines 8 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Spyre Therapeutics, Inc.’s own tally for this item (“Elect Director: Mark McKenna”): 65,608,709 for, 1,329,489 withheld, per its Form 8-K filed 2026-05-29 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 78,839,858 outstanding shares: 83% for, 2% withheld (85% of the company cast a for/withheld vote).
The 67 asset managers below cast 100% of the shares they voted on this item FOR (24,499,771 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 9,366,962 | 0 | 0 | 0 | For |
| Vanguard | 3,604,699 | 0 | 2 | 0 | For |
| Capital Group | 2,412,693 | 0 | 0 | 0 | For |
| BlackRock | 2,015,808 | 0 | 0 | 0 | For |
| Remedium Capital Partners, LLC | 1,456,231 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,262,166 | 0 | 0 | 0 | For |
| State Street | 658,406 | 0 | 190 | 0 | For |
| Charles Schwab | 561,767 | 0 | 0 | 0 | For |
| JPMorgan | 524,155 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 414,759 | 0 | 0 | 0 | For |
| Victory Capital | 326,801 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 323,584 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 65,274 | 0 | 252,945 | 0 | Abstain |
| First Trust | 178,135 | 0 | 0 | 0 | For |
| Hartford | 168,893 | 0 | 0 | 0 | For |
| Principal | 4,299 | 0 | 155,168 | 0 | Abstain |
| Equitable | 112,825 | 0 | 44,930 | 0 | For |
| TIAA | 144,924 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 82,062 | 0 | 0 | 0 | For |
| Brighthouse | 77,601 | 0 | 3,558 | 0 | For |
| Northwestern Mutual | 74,126 | 0 | 0 | 0 | For |
| Jackson National | 67,170 | 0 | 0 | 0 | For |
| John Hancock | 60,959 | 0 | 0 | 0 | For |
| Lincoln Financial | 52,674 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 49,311 | 0 | 0 | 0 | For |
Showing the 25 largest of 67 asset managers. See all 67 in the interactive database.
Combines 2 wordings of this item as funds reported it.
99.9% Majority: yes · of votes cast
Spyre Therapeutics, Inc.’s own tally for this item (“Proposal 3: The Company's stockholders ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026.”): 68,430,566 for, 670 against, per its Form 8-K filed 2026-05-29 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 78,839,858 outstanding shares: 87% for, 0.1% against (87% of the company cast a for/against vote).
The 67 asset managers below cast 100% of the shares they voted on this item FOR (24,953,007 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 9,366,962 | 0 | 0 | 0 | For |
| Vanguard | 3,604,701 | 0 | 0 | 0 | For |
| Capital Group | 2,412,693 | 0 | 0 | 0 | For |
| BlackRock | 2,015,808 | 0 | 0 | 0 | For |
| Remedium Capital Partners, LLC | 1,456,231 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,262,166 | 0 | 0 | 0 | For |
| State Street | 658,596 | 0 | 0 | 0 | For |
| Charles Schwab | 561,767 | 0 | 0 | 0 | For |
| JPMorgan | 524,155 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 414,759 | 0 | 0 | 0 | For |
| Victory Capital | 326,801 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 323,584 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 318,219 | 0 | 0 | 0 | For |
| First Trust | 178,135 | 0 | 0 | 0 | For |
| Hartford | 168,893 | 0 | 0 | 0 | For |
| Principal | 159,467 | 0 | 0 | 0 | For |
| Equitable | 157,755 | 0 | 0 | 0 | For |
| TIAA | 144,924 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 82,062 | 0 | 0 | 0 | For |
| Brighthouse | 77,601 | 0 | 3,558 | 0 | For |
| Northwestern Mutual | 74,126 | 0 | 0 | 0 | For |
| Jackson National | 67,170 | 0 | 0 | 0 | For |
| John Hancock | 60,959 | 0 | 0 | 0 | For |
| Lincoln Financial | 52,674 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 49,311 | 0 | 0 | 0 | For |
Showing the 25 largest of 67 asset managers. See all 67 in the interactive database.
99.9% fund support · no official result
The 67 asset managers below cast 99.9% of the shares they voted on this item FOR (23,490,367 for, 10,401 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 9,366,962 | 0 | 0 | 0 | For |
| Vanguard | 3,599,112 | 5,589 | 0 | 0 | For |
| Capital Group | 2,412,693 | 0 | 0 | 0 | For |
| BlackRock | 2,015,808 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,262,166 | 0 | 0 | 0 | For |
| State Street | 657,711 | 885 | 0 | 0 | For |
| Charles Schwab | 561,767 | 0 | 0 | 0 | For |
| JPMorgan | 524,155 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 414,759 | 0 | 0 | 0 | For |
| Victory Capital | 326,801 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 323,584 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 318,219 | 0 | 0 | 0 | For |
| First Trust | 178,135 | 0 | 0 | 0 | For |
| Hartford | 168,893 | 0 | 0 | 0 | For |
| Principal | 159,467 | 0 | 0 | 0 | For |
| Equitable | 157,755 | 0 | 0 | 0 | For |
| TIAA | 144,924 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 82,062 | 0 | 0 | 0 | For |
| Brighthouse | 77,601 | 3,558 | 0 | 0 | For |
| Northwestern Mutual | 74,126 | 0 | 0 | 0 | For |
| Jackson National | 67,170 | 0 | 0 | 0 | For |
| John Hancock | 60,959 | 0 | 0 | 0 | For |
| Lincoln Financial | 52,674 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 49,311 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 42,071 | 0 | 0 | 0 | For |
Showing the 25 largest of 67 asset managers. See all 67 in the interactive database.
Ranked by the number of Spyre Therapeutics, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 78,839,858 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 26.12% |
| 2 | Capital Group | 6.12% |
| 3 | RTW INVESTMENTS, LP | 5.32% |
| 4 | Vanguard | 5.26% |
| 5 | Fairmount Funds Management LLC | 5.10% |
| 6 | Venrock Adviser, LLC | 4.67% |
| 7 | T. Rowe Price | 3.76% |
| 8 | BlackRock | 3.40% |
| 9 | PERCEPTIVE ADVISORS LLC | 3.28% |
| 10 | Commodore Capital LP | 2.29% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| FMR (Fidelity) | 14.94% | 13F |
| Peter Harwin | 11.44% | 13D |
| Tomas Kiselak | 11.15% | DEF14A |
| Fairmount Healthcare Fund II L.P. | 10.49% | DEF14A |
| FMR LLC | 9.67% | DEF14A |
| BlackRock | 7.00% | 13F |
| Perceptive Advisors LLC | 5.48% | 13G |
| RTW Investments, LP | 5.39% | 13G |
| Vanguard Group | 5.12% | 13F |
| State Street | 3.31% | 13F |
Percentages above are of 78,839,858 shares outstanding, as reported by Spyre Therapeutics, Inc. on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Spyre Therapeutics, Inc.’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.
At Spyre Therapeutics, Inc.'s shareholder meeting held 2026-05-27, in the 2025-2026 proxy season, 220 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,665 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE… — FOR was 93% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Spyre Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-05-29.
Spyre Therapeutics, Inc. proxy season coverage: 2024-2025 · 2025-2026 (this page).